Bioresorbable cardiac stents have been ruled out for clinical use by a task force of European cardiologists as concerns remain about the increased risk of heart attack and stent-linked blockage with bioresorbable stents. In the journal Eurointervention, cardiologists stated that the new bioresorbable stents should undergo systematic non-clinical testing according to standardized criteria before they are evaluated in any clinical studies. The European Commission has asked the European Society of Cardiology and European Association of Percutaneous Cardiovascular Interventions to prepare a report on these stents. The important highlights of the report are: - the clinical evaluation plans for any bioresorbable stent should include data based on a medium-sized, randomised trial against drug-eluting stents to present clinical efficacy or non-inferiority. -An approved plan for a large-scale randomised clinical trial with planned long-term follows up should be presented. -The dual antiplatelet therapy required for patients implanted with a stent to prevent stent thrombosis might have to be continued for at least three years if implanted with Absorb or for whatever period of time it takes for the bioresorbable stent to be fully absorbed into the body.